These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7780885)

  • 1. Effect of calcitriol treatment on psoriasis in hemodialysis patient: a case report.
    Gao GW; Lin SH; Chyr SH; Lin YF; Tseng SS; Lu KC
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Mar; 55(3):263-5. PubMed ID: 7780885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis, 1,25(OH)2 vitamin D3 and renal failure.
    De Francisco AL; Cotorruelo JG; Riancho JA; Amado JA; Sanz De Castro S; Zubimendi A; Arias M
    Nephrol Dial Transplant; 1990; 5(4):293-4. PubMed ID: 2113226
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of psoriasis by oral calcitriol. A study of 5 cases and review of the literature].
    Boisseau-Garsaud AM; Legrain V; Hehunstre JP; Maleville J; Taïeb A
    Ann Dermatol Venereol; 1993; 120(10):669-74. PubMed ID: 8161095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.
    Takahashi S; Okada K; Kinosita Y; Yanai M; Kuno T; Nagura Y
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):377-82. PubMed ID: 8341016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis.
    Perez A; Raab R; Chen TC; Turner A; Holick MF
    Br J Dermatol; 1996 Jun; 134(6):1070-8. PubMed ID: 8763427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1 alpha,25-(OH)2D3 use on psoriasis and ichthyosis.
    Okano M
    Int J Dermatol; 1991 Jan; 30(1):62-4. PubMed ID: 1993570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of parathyroid hormone and 1,25 (OH)2D3 on nerve conductance in patients on maintenance hemodialysis.
    Ivić MA; Kostić S; Strahinjić S; Stefanović V
    Acta Med Iugosl; 1989; 43(5):349-55. PubMed ID: 2626971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results.
    Coen G; Mazzaferro S; Bonucci E; Ballanti P; Massimetti C; Donato G; Landi A; Smacchi A; Della Rocca C; Cinotti GA
    Miner Electrolyte Metab; 1986; 12(5-6):375-82. PubMed ID: 3492662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kukhtevich AV
    Ter Arkh; 1995; 67(5):27-31. PubMed ID: 7638771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypercalcemia and elevated 1,25(OH)2D3 levels in a dialysis patient with disseminated tuberculosis.
    Peces R; Alvarez J
    Nephron; 1987; 46(4):377-9. PubMed ID: 3658068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
    Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
    J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis.
    Kircik L
    J Drugs Dermatol; 2009 Aug; 8(8 Suppl):s9-16. PubMed ID: 19702031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,25(OH)2D3 and renal function. A controlled clinical study in normal elderly women.
    Jensen GF; Christiansen C; Transbøl I
    Acta Med Scand; 1982; 211(1-2):51-4. PubMed ID: 7041522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
    Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
    Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calciuric response to 1,25-(OH)2D3 in early renal failure.
    Cremer B; Lübbers E; Klooker P; Schmidt-Gayk H; Ritz E
    Miner Electrolyte Metab; 1985; 11(3):182-5. PubMed ID: 3839286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose oral calcitriol and changes of plasma 1,84iPTH in uremic children.
    Klaus G; Schmidt-Gayk H; Roth HJ; Ritz E; Mehls O
    Adv Perit Dial; 1994; 10():261-6. PubMed ID: 7999841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.